You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Litigation Details for In Re: Ozempic (Semaglutide) Patent Litigation (D. Del. 2022)


✉ Email this page to a colleague

« Back to Dashboard


In Re: Ozempic (Semaglutide) Patent Litigation (D. Del. 2022)

Docket ⤷  Sign Up Date Filed 2022-08-05
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Colm Felix Connolly
Jury Demand None Referred To Eleanor G. Tennyson
Patents 10,220,155; 10,335,462; 10,357,616; 10,376,652; 8,114,833; 8,129,343; 8,536,122; 8,684,969; 8,920,383; 9,108,002; 9,132,239; 9,457,154; 9,616,180; 9,687,611; 9,775,953; 9,861,757; RE46,363
Link to Docket External link to docket
Small Molecule Drugs cited in In Re: Ozempic (Semaglutide) Patent Litigation
The small molecule drugs covered by the patents cited in this case are ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , and ⤷  Sign Up .
Biologic Drugs cited in In Re: Ozempic (Semaglutide) Patent Litigation

The biologic drugs covered by the patents cited in this case are ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , and ⤷  Sign Up .

Details for In Re: Ozempic (Semaglutide) Patent Litigation (D. Del. 2022)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 External link to document
2022-08-05 1 Order ; 9,616,180; 9,687,611; 9,775,953; 9,861,757; 10,220,155; 10,335,462; 10,357,616; 10,376,652; and 11,097,063… infringed two or more of the Ozempic patents. While the patents asserted in each action vary somewhat…Valsartan) Patent Litig., 437 F. Supp. 3d 1372, 1373 (J.P.M.L. 2020); In re Palbociclib Patent Litig., 396…unique patents, this may be a temporary distinction. Further, many of the “non-common” patents asserted…West Virginia action derive from the same patent family as patents asserted in the Delaware actions, and External link to document
2023-03-22 112 ANDA Form U.S. Patent No. 9,687,611 expires on 2/27/2027; U.S. Patent Nos. 8,920,383, 9,775,953, 10,220,155, and…U.S. Patent No. 9,687,611 expires on 2/27/2027; U.S. Patent Nos. 8,920,383, 9,775,953, 10,220,155, and…of Expiration of Patent: U.S. Patent No. 8,114,833 expires on 8/13/2025; U.S. Patent Nos. 8,684,969 and…expire on 1/20/2026; U.S. Patent No. 8,536,122 expires on 3/20/2026; Patent No. RE46,363 expires on 8/…expire on 7/17/2026; U.S. Patent No. 9,457,154 expires on 9/27/2027; U.S. Patent No. 9,132,239 expires on External link to document
2023-03-22 113 Patent/Trademark Report to Commissioner of Patents 9,616,180; ;9,687,611; 9,775,953; 9,861,757; ;10,220,155; 10,335,462; 10,357,616; ;10,376,652; 11,097,… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,114,833; 8,129,343…Semaglutide) Patent Litigation 5 August 2022 1:22-md-03038 835 Patent - Abbreviated External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.